1 Case editor, Royal Adelaide Hospital, Adelaide, South Australia
2 Discussant, professor, consultant intensivist, Flinders Medical Centre, Adelaide, South Australia
3 Consultant pathologist, SA Pathology, Adelaide, South Australia
4 Consultant intensivist, clinical in-charge, Royal Adelaide Hospital, Adelaide, South Australia
5 South Australian Medical Imaging, Adelaide, South Australia
Correspondence to: Prajeshsinh Jadeja — Prajeshsinh.Jadeja@sa.gov.au
Cite as: Jadeja P, Bersten A, Gomes D, Reddi B, Li Y. Clinicopathological Conference: A healthy 53-year-old man with rapidly progressive respiratory failure and diffuse pulmonary infiltrates. South Aust J Med. 2026;1(2):e0011.
DOI: 10.66861/MIPX3336 Open access · CC BY 4.0
Submitted 2 Jul 2026 Accepted 24 Aug 2026 Published 1 Sep 2026
Abstract
A previously healthy 53-year-old man developed rapidly progressive respiratory failure, which required maximal intensive care therapy with extracorporeal membrane oxygenation, before he died. His journey was complicated by several competing pathological processes. As his condition continued to deteriorate, clinicians repeatedly reconsidered the working diagnosis but were unable to identify a single unifying explanation. This case highlights the difficulty of diagnosing rare causes of rapidly progressive diffuse lung disease when the results of initial investigations are non-specific. It emphasises the importance of revisiting the differential diagnosis when patients fail to improve as expected, and demonstrates the unique value of post-mortem examination in resolving complex diagnostic problems.
Editor’s preface
Our Clinicopathological Conference series exists to show diagnostic reasoning as it actually happens — uncertain, contested, and revised in real time. This case, in which a fit 53-year-old man’s rapid decline outpaced every working theory offered by the team caring for him, is a study in intellectual humility. Only the post-mortem, in the end, told the whole story.
— The Editors
A Clinicopathological Conference is the written record of an actual multidisciplinary clinical conference. A moderator presents a real case to a discussant, who reasons towards a diagnosis. A radiologist interprets the imaging, and a pathologist delivers the definitive diagnosis. The written article faithfully represents the conference proceedings and may be enhanced to ensure completeness and educational value. Clinicopathological Conferences are peer reviewed and carry learning objectives to support continuing professional development.
Learning objectives
By the end of this article, readers should be able to:
- recognise the clinical, laboratory and radiological features of fulminant diffuse lung disease, which should prompt consideration of uncommon infectious causes
- apply a structured diagnostic approach when a patient with severe respiratory failure fails to improve despite appropriate therapy
- recognise the importance of revisiting a working diagnosis when the clinical course becomes inconsistent with the presumed diagnosis
- explain how the angio-invasive behaviour of mucormycosis results in thrombosis, tissue infarction, cavitation and multisystem organ dysfunction
- describe the diagnostic challenges of pulmonary mucormycosis, including the limitations of conventional microbiology and the role of tissue sampling and molecular diagnostics.
Case history
PATRICK RUSSELL—moderator. A previously healthy 53-year-old man presented to a regional hospital with a five-day history of progressive lethargy, dyspnoea and subjective fevers. He had been fit and active, regularly running up to 10 km each day, until one week before admission. His breathlessness then deteriorated rapidly over several days, leaving him unable to walk without assistance from family members because of increasing respiratory distress. He reported fatigue, reduced appetite and only a minimal cough. Chest pain and haemoptysis were absent.
His medical history was unremarkable: no regular medications or history of immunosuppression. Approximately one month before presentation, he and several family members had experienced a mild COVID-19 infection. He worked as a graphic designer and reported frequent cannabis use in previous years by smoking. He had recently returned to Australia from living in the United States for five years, including travel through the desert regions of Arizona 18 months before this admission. During the month before presentation to hospital, he had been house-sitting in the Adelaide Hills, spending considerable time gardening outdoors and in contact with a pet dog at the property. There had been no exposure to birds.
At presentation, he was in severe respiratory distress. Although he was receiving 15 L/min oxygen via a non-rebreather mask, saturations could not be maintained above 80%, thus endotracheal intubation and transfer to a tertiary Intensive Care Unit were required. During retrieval, oxygen saturations repeatedly fell below 70%, even with maximal ventilatory support. On arrival, he required vasopressor support. Examination of his chest revealed bilateral inspiratory crackles.


Investigations
Initial laboratory investigations revealed marked systemic inflammation, neutrophilic leukocytosis, hyperlactataemia, and mixed metabolic and respiratory acidosis while the patient was receiving maximal oxygen therapy.
Additional abnormalities included acute kidney injury, hypoalbuminaemia, elevated ferritin, elevated lactate dehydrogenase and a rising troponin. Electrocardiography showed sinus rhythm without ischaemic changes. Rapid SARS-CoV-2 antigen testing and multiplex respiratory viral testing were negative.
DR YAMIN LI Chest radiography showed extensive bilateral pulmonary infiltrates, in a pattern suggestive of a diffuse inflammatory or atypical infective process, without pleural effusions (Figure 1). Computed tomographic pulmonary angiography (CTPA) excluded pulmonary embolism but revealed widespread bilateral ground-glass and consolidative airspace opacities (Figure 2). A high-resolution CT scan performed later in the admission showed rapidly progressive pulmonary abnormalities despite initial treatment, including worsening consolidation, evolving bronchiectatic change, cavitation and bilateral pneumothoraces (Figure 3). A subsequent CT of the chest, abdomen and pelvis showed further pulmonary destruction with progressive consolidation and cavitary change (Figure 4). Additional extrapulmonary abnormalities included bilateral renal hypodensities concerning for renal infarction, raising the possibility of a disseminated pathological process extending beyond the lungs. Chronic bilateral mastoid effusions and inflammatory changes within the paranasal sinuses were also present but had not evolved significantly when compared with earlier imaging during admission.
Problem representation
A 53-year-old man presented with dyspnoea and was found to have diffuse bilateral pulmonary infiltrates, profound hypoxaemia and rapidly progressive respiratory failure. The clinical challenge was to determine its underlying cause.
Conference discussion
DR PRAJESHSINH JADEJA—case editor. It was unclear whether his presentation reflected a primary bacterial lung infection complicated by sepsis and respiratory failure, or a non-infectious multisystem disease presenting with a similar clinical picture.
Several features of the history were likely to shape subsequent diagnostic reasoning. Recent gardening in the Adelaide Hills and travel through the southwestern United States raised the possibility of infection acquired through environmental or travel-related exposure. Further, a preceding respiratory illness among household contacts supported an infectious trigger. Equally important were the absent features, including chest pain, haemoptysis, tobacco exposure, recent recreational drug use, known immunosuppression and significant occupational exposures.
The conference discussion therefore centred on identifying the unifying process responsible for this fulminant diffuse lung injury before narrowing the differential diagnosis to specific disease entities.
Differential diagnosis
PROFESSOR ANDREW BERSTEN—discussant. The striking feature of this case was the pace of deterioration. A previously healthy, physically active 53-year-old man had progressed from running 10 km each day to requiring mechanical ventilation and vasopressor support within a week.
A practical approach was to classify the differential diagnosis into infectious and non-infectious causes of diffuse pneumonitis and acute respiratory distress syndrome (see Table 1). Infectious considerations included common and atypical bacterial pathogens, viral pneumonitis, fungal infection, opportunistic infection and zoonotic disease. Non-infectious possibilities included immune-mediated lung disease, pulmonary vasculitis, acute eosinophilic pneumonia, drug-induced or toxin-induced lung injury, and environmental exposure-related pneumonitis.
| Infectious | Non-infectious |
|---|---|
| Common bacterial pneumonia | Pulmonary vasculitis (e.g. ANCA-associated vasculitis, anti-GBM disease) |
| Atypical bacterial infection | Acute eosinophilic pneumonia |
| Viral pneumonitis | Drug-induced lung injury |
| Fungal infection | Inhalational/toxic lung injury |
| Zoonotic infection | Environmental exposure-related pneumonitis |
| Opportunistic infection | Immune-mediated pneumonitis |
| Cryptogenic organising pneumonia |
The initial working diagnosis was severe community-acquired pneumonia. The rapid onset of symptoms, neutrophilic leukocytosis, markedly elevated inflammatory markers, and bilateral pulmonary infiltrates all favoured an infective process. However, the paucity of cough, together with the diffuse radiological abnormalities and respiratory failure, appeared disproportionate to routine bacterial pneumonia, even in the setting of an acute lung injury. Further, the presence of a noradrenaline requirement and acute kidney injury raised concern for severe bacterial sepsis or another systemic pathological process.
Viral pneumonitis was also considered. Recent infection with SARS-CoV-2 made residual infection or related complications plausible early in the course. However, negative SARS-CoV-2 testing made this diagnosis progressively less likely. Other viral pneumonitides remained possible, but the absence of microbiological confirmation on multiplex respiratory viral testing excluded these.
Recent gardening in the Adelaide Hills raised the possibility of an environmentally acquired infection, such as Legionella, as well as a hypersensitivity pneumonitis. The patient’s recent travel through the southwestern United States prompted consideration of geographically acquired fungal pathogens, such as Coccidioides. Fungal and opportunistic infections remained lower on the differential in the absence of recognised immunosuppression, although the severity of illness warranted exclusion; HIV serology and sputum cultures were sent accordingly.
Pneumocystis jirovecii pneumonia was considered because of the diffuse infiltrates, severe hypoxaemia and elevated lactate dehydrogenase, but the absence of recognised risk factors made it less likely. Tuberculosis ranked low on the differential given the absence of haemoptysis, the short symptom duration and the lack of epidemiological risk factors.
Non-infectious causes, such as acute eosinophilic pneumonia, hypersensitivity pneumonitis, organising pneumonia and pulmonary vasculitis, were a consideration. However, the patient’s clinical presentation and the limited evidence supporting an inflammatory aetiology favoured infection as the more likely diagnosis. These conditions remained important considerations, and the failure of initial therapy warranted their reassessment.
The severe hypoxaemia and troponin elevation could point towards a pulmonary embolism, but this was effectively excluded by computed tomographic pulmonary angiography.
At this stage, severe infectious pneumonitis remained the leading differential diagnosis, although the responsible pathogen and whether infection alone could fully explain the presentation remained uncertain.
Additional clinical course
DR PRAJESHSINH JADEJA AND DR BENJAMIN REDDI On arrival at the Intensive Care Unit, maximal ventilatory support failed to maintain saturations above 70%. Bedside echocardiography showed mild biventricular dysfunction in addition to the patient’s inotropic requirement, prompting the addition of inhaled nitric oxide. Given the additional risk for ventilator-associated lung injury, veno-venous extracorporeal membrane oxygenation (VV ECMO) was commenced shortly after admission. Empirical antimicrobial therapy was initiated with piperacillin-tazobactam, vancomycin and azithromycin for severe community-acquired pneumonia.
Although the patient maintained stable gas exchange on VV ECMO, the underlying diagnosis remained unclear. Early bronchoscopy was macroscopically normal, and initial microbiological testing did not yield typical or atypical pathogens.
Despite only a short symptomatic prodrome, the severity and widespread distribution of the pulmonary changes on imaging suggested a rapidly progressive disease process and initially favoured severe community-acquired pneumonia.
As investigations continued, alternative explanations began to emerge. Bronchoalveolar lavage showed a predominantly neutrophilic inflammatory pattern with a small eosinophilic component. Simultaneously, the peripheral blood eosinophil count rose progressively. These findings raised the possibility of an inflammatory lung disease; organising pneumonia and eosinophilic pneumonitis emerged as the leading considerations. As diagnostic uncertainty persisted, multiple specialist teams became involved. The infectious diseases team initially favoured an atypical infectious process, and the respiratory medicine team increasingly considered organising pneumonia as the dominant pathology. The immunology team reviewed the case in the context of recent COVID-19 exposure and eosinophilia, raising the possibility of a post-viral hyperinflammatory syndrome that was analogous to multisystem inflammatory syndrome in adults. High-dose corticosteroid therapy produced an initial improvement in oxygenation and inflammatory markers, further supporting an inflammatory lung process. This improvement proved transient; the patient deteriorated even as therapy continued

The findings on repeat imaging challenged the diagnosis of uncomplicated organising pneumonia.
Aggressive supportive care did not prevent further decline in respiratory function. Lung-protective ventilation strategies were employed throughout the admission in conjunction with VV ECMO support. Bilateral pneumothoraces required pleural drainage, and persistent air leaks further complicated respiratory management. Bilateral pleural drains were also required for recurrent pleural effusions associated with pulmonary oedema. Pleural fluid analysis showed an exudative inflammatory effusion with markedly elevated lactate dehydrogenase, high white cell counts and polymorphonuclear predominance, although repeated cultures remained negative. These findings reinforced the presence of severe pulmonary inflammation while failing to identify an underlying pathogen.
By this stage, Aspergillus fumigatus had been repeatedly isolated from respiratory specimens, and bronchoalveolar lavage galactomannan testing was strongly positive. Whether these findings represented invasive disease or colonisation remained uncertain in the setting of severe structural lung injury. Repeated blood cultures, autoimmune investigations and opportunistic infection screening remained unrevealing. Consequently, over the subsequent days, antifungal therapy was escalated for presumed infection, while cyclophosphamide and intravenous immunoglobulin were introduced to treat a competing inflammatory diagnosis.

After more than three weeks of ECMO support, the patient developed worsening acute kidney injury, escalating vasopressor requirements and progressive multi-organ dysfunction. Refractory hyperkalaemia complicated his renal failure, resulting in recurrent arrhythmias requiring cardioversions. His condition continued to deteriorate while he received maximal antimicrobial, antifungal, immunosuppressive and organ-supportive therapies. Care was redirected after discussion with the family, and he died shortly after. With the family’s consent, an autopsy was performed to establish the underlying diagnosis.
Post-mortem findings
DR DEBORAH GOMES—pathologist. Post-mortem examination showed extensive abnormalities involving the lungs and multiple extrapulmonary organs.
The lungs were markedly enlarged, with a combined weight of 2,990 g. Gross examination revealed diffuse bilateral consolidation with widespread replacement of normal aerated lung parenchyma by firm, pale tissue (Figure 5). Multifocal areas of infarct-like necrosis were present throughout both lungs. This was accompanied by bilateral fibrous pleural adhesions and bullous change, most prominent within the right middle lobe.

Microscopic examination showed widespread vascular abnormalities involving all lobes of both lungs. Numerous pulmonary vessels contained fibrin-rich occlusive thrombi associated with fungal elements, some of which extended into vessel walls and surrounding tissue. These changes were often accompanied by extensive pulmonary infarction (Figure 6).

At higher magnification, the fungal elements could be seen to consist of broad, ribbon-like pauciseptate hyphae with angular branching. Occasional spore-bearing structures were also identified (Figure 7).

Additional abnormalities were identified outside the lungs. Multiple pale wedge-shaped and nodular lesions were present within both kidneys, corresponding microscopically to areas of vascular occlusion and tissue infarction (Figure 8). Similar fungal elements were identified within the spleen and thyroid gland.

No significant background interstitial lung disease was identified within the preserved areas of lung parenchyma. Virological testing performed on post-mortem tissue samples from the lung, heart and intestine was negative for SARS-CoV-2.
Pathology discussion
DR DEBORAH GOMES Post-mortem examination confirmed the presence of severe and destructive pulmonary disease. It also identified the presence of numerous thrombi which contained broad, ribbon-like, pauciseptate fungal hyphae with irregular right-angle branching, infiltrating blood vessel walls and accompanied by extensive pulmonary infarction. Although also seen in other fungal disease, including the more common Aspergillus infections, prominent angioinvasion with vascular thrombosis and extensive tissue infarction is characteristic of mucormycosis and explains the fulminant clinical course observed in this patient.
SARS-CoV-2 testing on post-mortem tissue was negative, providing no pathological evidence of active COVID-19 pneumonitis. This conflicts with one of the leading diagnoses considered during life.
The principal pathological differential diagnosis was invasive pulmonary aspergillosis and other invasive mould infections. Histologically, however, the broad pauciseptate hyphae and irregular right-angle branching were characteristic of fungi within the order Mucorales, distinguishing them from the narrow, septate hyphae with acute-angle branching typical of Aspergillus species.
Histology can confidently identify the pattern of invasive mucormycosis but cannot reliably distinguish between individual genera or species within Mucorales. Correlation with microbiological investigations was therefore required; in this case, it confirmed Rhizopus microsporus.
The pathological findings closely reconciled the patient’s clinical presentation. Angioinvasion results in vascular occlusion, tissue ischaemia and infarction, providing a pathological explanation for the rapidly progressive pulmonary destruction, cavitation, persistent air leaks, refractory hypoxaemia and renal infarction identified during life. The widespread vascular invasion also explains why conventional antimicrobial therapy and organ support were unable to halt disease progression.
This case illustrates the strengths and limitations of pathology. Histological examination identified an invasive mould infection and distinguished mucormycosis from other important fungal pathogens. This distinction had significant therapeutic implications. However, pathology alone could not determine when the infection was acquired, whether it was the primary pathological process or a secondary complication of immunosuppressive therapy, or which host factors predisposed the patient to infection.
Definitive diagnosis therefore depended on integrating the pathological findings with the clinical course, imaging, microbiology and molecular testing, highlighting the value of a multidisciplinary clinicopathological approach.
Cause of death
The cause of death is recorded in the format used on the Australian Medical Certificate of Cause of Death. Line 1a records the immediate cause of death; line 1b records the underlying condition that gave rise to it. This format is recommended by the Australian Bureau of Statistics and reflects the WHO international standard for mortality reporting.
1a: Severe necrotising pneumonia
1b: Disseminated angio-invasive mucormycosis due to R. microsporus
Clinicopathological correlation
DR DEBORAH GOMES AND DR PRAJESHSINH JADEJA The autopsy showed disseminated angio-invasive mucormycosis caused by R. microsporus, with extensive pulmonary involvement and dissemination to the kidneys, spleen and thyroid. Histologically, broad pauciseptate fungal hyphae invaded vessel walls, resulting in vascular thrombosis, pulmonary infarction and widespread tissue necrosis. These findings provided a unifying explanation for the patient’s rapidly progressive respiratory failure and eventual multiorgan failure.
The pathological diagnosis differed from the leading clinical differentials of bacterial pneumonia, post-viral hyperinflammatory syndrome or severe atypical infection. Progressive peripheral eosinophilia, transient clinical improvement following corticosteroid therapy, and repeatedly negative early microbiological investigations all strengthened consideration of an inflammatory or autoimmune process during life. However, the autopsy showed no histological evidence of an underlying inflammatory lung disease or significant eosinophilic tissue infiltration. Consequently, the pathological findings did not support eosinophilic pneumonia or organising pneumonia, nor did they account for the eosinophilia observed on pleural fluid or blood film during admission; the eosinophilia remains unexplained.
Repeated isolation of Aspergillus fumigatus and strongly positive bronchoalveolar lavage galactomannan further complicated diagnostic interpretation, representing either secondary airway colonisation within extensively necrotic lung tissue or, less likely, concomitant fungal infection. Blood cultures remained negative and no causative organism was identified before death, although the infection was widely disseminated. This is consistent with the tendency of Mucorales to invade tissues and blood vessels without causing sustained fungaemia. In addition, recovery of Mucorales from culture is often limited by fragile hyphae, extensive tissue necrosis and prior antifungal therapy. Ultimately, only post-mortem examination reconciled the clinical, radiological, microbiological and pathological findings into a single diagnosis.
What this case teaches
DR PRAJESHSINH JADEJA AND DR BENJAMIN REDDI First, a lack of improvement after initial treatment should prompt a reassessment of the working diagnosis. This case illustrates that pulmonary mucormycosis may be difficult to diagnose even with rigorous multidisciplinary investigation. As the patient deteriorated, clinicians from multiple specialties repeatedly reconsidered the diagnosis. However, this careful and stepwise reassessment did not lead to recognition of pulmonary mucormycosis, which was identified only at autopsy. This does not reflect a failure of clinical practice but rather the inherent difficulty of diagnosing a rare disease that frequently mimics more common infectious and inflammatory conditions, and often requires tissue confirmation.1 Population-level data further suggest that up to 29% of the cases of pulmonary mucormycosis occur without recognised predisposing host factors, underscoring that apparent immunocompetence does not exclude the diagnosis.2
Second, this case illustrates the devastating consequences of angio-invasive fungal infection. At autopsy, vascular invasion by R. microsporus was found to have caused extensive thrombosis, infarction and tissue necrosis, accounting for the refractory hypoxaemia, progressive cavitation, pneumothoraces and eventual renal dissemination. This underlying vascular pathology also explains why even maximal respiratory support and ECMO could not reverse the disease process. Mucormycosis is caused by filamentous fungi of the order Mucorales—most commonly Rhizopus species—which are typically acquired through inhalation of environmental spores and characteristically invade blood vessels. Their pathogenicity is enhanced by several mechanisms, including upregulation of iron-acquisition pathways. The organism produces proteases that directly promote vascular invasion and thrombus formation. These features may account for the fulminant clinical trajectory, even in apparently immunocompetent patients.3
Third, individual clinical features should be interpreted within the broader clinical context. Progressive eosinophilia, transient improvement following corticosteroid therapy and repeatedly negative early microbiological investigations supported the diagnoses of organising pneumonia or a post-viral inflammatory lung disease. This case reinforces the importance of reconsidering invasive fungal infection before escalating immunosuppression in patients with rapidly progressive destructive lung disease, particularly when diagnostic uncertainty persists. Yet this is rarely a straightforward decision. When a patient is deteriorating rapidly, and investigative results remain non-specific, the risks of withholding immunosuppressive therapy are real and immediate, while the possibility of an underlying fungal infection may not yet be supported by any convincing evidence. The decision when, and whether, to escalate to agents such as cyclophosphamide, which carries its own significant toxicity, requires careful weighing of competing risks in the absence of diagnostic certainty. Corticosteroid therapy, prescribed in this case for suspected inflammatory lung disease, is a recognised risk factor for mucormycosis because it impairs the fungicidal activity of neutrophils and macrophages.4 The COVID-19 pandemic has drawn renewed attention to this association. In addition to the immunosuppressive effects of corticosteroids, SARS-CoV-2 infection may cause immune dysfunction through profound lymphopenia, impaired CD4 and CD8 T cell function, and hyperferritinaemia-associated iron dysregulation—changes that may independently promote Mucorales growth, even in patients who have not received prior immunosuppressive therapy.5,6
Further, an elevated lactate dehydrogenase (LDH) level may provide an additional clue in severe diffuse lung disease. Although non-specific, the progressive rise in LDH in this case likely reflected extensive pulmonary tissue injury, infarction and necrosis. Elevated LDH has previously been reported in pulmonary mucormycosis and may indicate parenchymal destruction when the clinical trajectory appears disproportionate to the presumed diagnosis.7 In future cases, the combination of progressive LDH elevation, worsening structural lung destruction on imaging, and failure to respond to appropriate antimicrobial therapy could prompt renewed diagnostic reassessment. This case may encourage clinicians to consider earlier lung biopsy, where clinically feasible. Here, however, the patient was too clinically unstable to safely undergo biopsy. Had biopsy been feasible, sampling error could have been a significant limitation. The fungal elements were largely confined to blood vessels with moderately thick walls—structures that are hazardous to target directly. The surrounding tissue captured in a standard biopsy was unlikely to be diagnostic. When conventional testing is unrevealing, advanced molecular investigations such as metagenomic next-generation sequencing may also warrant consideration.
Finally, this case highlights the considerable diagnostic and therapeutic challenges posed by pulmonary mucormycosis. Definitive diagnosis frequently requires tissue sampling, yet critically ill patients may be too unstable to undergo invasive procedures. In this case, repeated bacterial cultures, autoimmune investigations and tests for opportunistic infections were unrevealing, while positive Aspergillus cultures and galactomannan results further complicated the diagnostic picture. Although early initiation of liposomal amphotericin B is associated with improved survival, empirical treatment can be difficult to justify without convincing microbiological evidence given its substantial toxicity, particularly nephrotoxicity.7 This dilemma is amplified by the rarity of pulmonary mucormycosis in apparently immunocompetent individuals, leading clinicians to assign a low pretest probability to the diagnosis.
Emerging molecular techniques, including polymerase chain reaction (PCR) and metagenomic next-generation sequencing (mNGS), applied to bronchoalveolar lavage fluid or tissue, may enable earlier identification of Mucorales than conventional culture.8 Although access to these technologies is increasing in Australia, availability remains varied between centres. In pulmonary mucormycosis, bronchoalveolar lavage mNGS has achieved detection rates of up to 100% in some studies, compared with culture positivity rates as low as 7%, while also providing a substantially shorter turnaround time.9 Pan-Mucorales PCR may detect infection seven to eight days earlier than conventional culture and increase overall case detection by more than 30%.10 Further, mNGS can provide species-level identification, including recognition of R. microsporus, when culture is negative or delayed.11 This capability is directly relevant to the present case, in which the diagnosis was not established before death. As access to PCR and mNGS expands across Australia, these technologies may become part of standard practice and should be considered early in rapidly progressive pulmonary disease when conventional investigations are unrevealing and tissue sampling is not feasible.
This case reinforces the value of persistently reassessing the working diagnosis when a patient’s clinical course does not follow the expected trajectory, even when appropriate treatment has been given.
References
- Skiada A., Lanternier F., Groll A.H., Pagano L., Zimmerli S., Herbrecht R., et al. Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3). Haematologica. 2013 Apr; 98 (4): 492-504. doi: 10.3324/haematol.2012.065110.
- Peng M, Meng H, Sun Y, Xiao Y, Zhang H, Lv K, et al. Clinical features of pulmonary mucormycosis in patients with different immune status. J Thorac Dis. 2019;11(12):5042–5052. doi:10.21037/JTD.2019.12.53
- Sannathimmappa MB, Nambiar V, Aravindakshan R. Storm of a rare opportunistic life-threatening mucormycosis among post-COVID-19 patients. Int J Crit Illn Inj Sci. 2022;12(1):38–46. doi:10.4103/ijciis.ijciis_48_21
- Al-Tawfiq JA, Alhumaid S, Alshukairi AN, Temsah M-H, Barry M, Al Mutair A, et al. COVID-19 and mucormycosis superinfection: the perfect storm. Infection. 2021;49:833–853. doi:10.1007/S15010-021-01670-1
- Kumar D, Ahmad F, Kumar A, Bishnoi M, Grover A, Rewri P. Risk factors, clinical manifestations, and outcomes of COVID-19-associated mucormycosis and other opportunistic fungal infections. Cureus. 2023;15(9):e46289. doi:10.7759/cureus.46289
- Bhatt K, Agolli A, Patel MH, Garimella R, Devi M, Garcia E, et al. High mortality co-infections of COVID-19 patients: mucormycosis and other fungal infections. Discoveries (Craiova). 2021;9(1):e126. doi:10.15190/d.2021.5
- Choi H, Lee H, Jeon K, Suh GY, Shin S, Kim HK, et al. Factors affecting surgical resection and treatment outcomes in patients with pulmonary mucormycosis. J Thorac Dis. 2019;11(3):892–900. doi: 10.21037/jtd.2019.01.75
- Cheng X., Li T., Wu F. and Liu D.Clinical Manifestation, mNGS Based Diagnosis and Treatment of Pulmonary Mucormycosis with Rhizopus delemar in a Diabetic Patient. Infect Drug Resist. 2024; 17: 1379-1384. doi: https://doi.org/10.2147/IDR.S454029
- Yao X, Sang H, Gao S, Hu X, Yan J, Liu T, et al. Diagnostic utility of bronchoalveolar lavage mNGS for pulmonary mucormycosis: a single-centre retrospective cohort study. Infect Drug Resist. 2025;18:6469–80. doi:10.2147/IDR.S542578
- Haas A, Hanson KE. Clinical test comparison for improved diagnosis of mucormycosis. Am J Clin Pathol. 2024;162(Supp 1):S165. doi:10.1093/ajcp/aqae129.364
- Hai L, Li P, Xiao Z, Zhou J, Xiao B, Zhou L. Rhizopus microsporus and Mucor racemosus coinfection following COVID-19 detected by mNGS: a case of disseminated mucormycosis. Heliyon. 2024;10:e25840. doi:10.1016/j.heliyon.2024.e25840
Acknowledgements: We thank the clinical and laboratory staff involved in the patient’s care and diagnostic evaluation, as well as the patient’s family for providing consent for the post-mortem examination and publication of this clinicopathological conference. The authors wish to acknowledge the valuable contribution of their anonymous reviewer.
Funding statement: No funding was received for this work.
Conflict of interest statement: The authors declare no conflicts of interest.
Ethics approval: Written consent for publication was obtained from the next of kin.
Data availability statement: Not applicable.
Use of AI tools: Generative AI (ChatGPT) was used to assist with language editing of the Discussion section. The authors reviewed and take responsibility for all content.